Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35727698.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1257.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Understanding metabolic dependencies and their therapeutic vulnerabilities is key to precision oncology. Malic enzyme 1 (ME1) is frequently overexpressed in cancers with protumorigenic effects. In contrast, consistent loss of ME1 expression in synovial sarcoma compared with other sarcomas indicates a unique ferroptosis liability for precision therapy in this form of cancer. See related article by Brashears et al., p. 3573.
Medical subject headings
- Ferroptosis
- Sarcoma, Synovial